Canaccord Genuity Group Upgrades Bioventus (NYSE:BVS) to Buy

Canaccord Genuity Group upgraded shares of Bioventus (NYSE:BVS – Free Report) from a hold rating to a buy rating in a research note issued to investors on Thursday, Benzinga reports. The firm currently has $7.00 price objective on the stock, up from their prior price objective of $3.66. A number of other equities research analysts […]

Related Keywords

United States , Zurcher Kantonalbank Zurich Cantonalbank , Craig Hallum , Lazard Asset Management , Group Plc , Canaccord Genuity Group , Financial Services Group Inc , Bioventus Inc , Free Report , Genuity Group , Stock Down , Get Free Report , Services Group , Asset Management , Kantonalbank Zurich Cantonalbank , General Group Plc , Bioventus Daily , Bioventus , Nyse Bvs , Cbvs , Medical , Upgrade , Canaccord Genuity Group Inc ,